S-531011

Investigational

Description

S-531011 is an investigational medication currently being studied in clinical trials for colorectal cancer. It is being evaluated in combination with other drugs, fruquintinib and pembrolizumab, specifically for patients with microsatellite stable (MSS) or predicted microsatellite instability-high (pMMR) metastatic colorectal cancer. The trials are designed to assess the safety and effectiveness of these combinations. S-531011 is given intravenously every three weeks. The specific mechanism of action and molecular target of S-531011 are still under investigation.

Mechanism of Action

The specific way S-531011 works (its mechanism of action) is currently being studied in clinical trials. It is being investigated as part of combination therapies with fruquintinib and pembrolizumab for certain types of metastatic colorectal cancer (MSS/pMMR). The exact molecular target is being characterized.

Side Effects

As S-531011 is an investigational drug in early-phase trials (Phase 1b/II) The full range of potential side effects is still being evaluated. Information about side effects is being collected during the clinical trials to determine the drug's safety profile. Common side effects associated with intravenous medications or the combination drugs (fruquintinib Pembrolizumab) might include fatigue Diarrhea Nausea Skin reactions Or changes in blood counts But specific side effects related to S-531011 are still being determined.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07591597 med_phase_prefix1

Not yet recruiting

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

Quick Info

Category	Investigational
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.